Ocugen, Inc. OCGN

OCGN Company Overview

Ocugen, Inc. is a U.S.-based biotechnology company focused on developing gene therapies, biologics, and vaccines targeting ophthalmic diseases, infectious diseases, and rare conditions. The company operates primarily within the biotechnology and biopharmaceutical industries, with a strategic emphasis on therapies for underserved medical needs, particularly inherited retinal diseases and retinal degenerative disorders. Its core revenue and valuation drivers have historically been tied to clinical-stage product development, licensing arrangements, strategic collaborations, and capital market financing rather than large-scale commercial product sales.

The company’s principal programs include modifier gene therapies for retinal diseases, novel biologic candidates for ophthalmology, and historically vaccine-related collaborations. Ocugen evolved from a biopharmaceutical development company founded in 2013 through the merger of Histogenics Corporation and Ocugen, Inc. in 2019, after which it adopted the Ocugen name and ticker symbol OCGN. The company gained broader market visibility during the COVID-19 pandemic through its vaccine commercialization partnership involving Covaxin, although its long-term strategic focus has increasingly centered on ophthalmology and gene therapy development.